Premium
Improvement of juvenile dermatomyositis with calcinosis universalis after treatment with intravenous immunoglobulin
Author(s) -
YANG MingChun,
LEE JyhHong,
YANG YaoHsu,
CHIANG BorLuen
Publication year - 2008
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2008.00336.x
Subject(s) - juvenile dermatomyositis , medicine , dermatomyositis , calcinosis , hydroxychloroquine , dermatology , disease , calcification , covid-19 , infectious disease (medical specialty)
Juvenile dermatomyositis is a chronic multisystemic disease. It is believed to be of autoimmune aetiology and is characterized by the presence of vasculitis affecting striated muscle and skin. Calcinosis occurs in about 40% of cases. We report a case of a 10‐year‐old girl diagnosed with juvenile dermatomyositis who presented with difficulty in walking and inability to completely extend the four extremities due to calcinosis universalis. Calcinosis had progressed despite a 3‐year administration of diltiazem, hydroxychloroquine, aluminium hydroxide, cyclosporin, and probenecid. The introduction of monthly intravenous immunoglobulin therapy for 15 months lessened disease activity, and markedly regressed calcinosis, and improved functional outcome.